EHA 2023 | Phase I study of CD123 NK cell engager SAR443579 in R/R AML, B-ALL or HR-MDS
Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY, discusses the results of a Phase I study of the CD123 natural killer (NK) cell engager SAR443579 in patients with relapsed/refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndromes (HR-MDS; NCT05086315). The study reported encouraging efficacy results and was very well tolerated. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Dr Stein has actually presented at EHA 2023 on NK-cell engager targeting CD123, which is showing very promising data. This was a Phase I study, dose finding study, where several dosages were given. And what was very encouraging about this is, one: it is not toxic, it’s very well tolerated regimen – we always worry about, you know, cell engagers as having significant cytokine release syndrome which has marred the development of some of these agents, but this particular one, we seem to actually not have very significant cytokine release syndrome – so very well tolerated...
Dr Stein has actually presented at EHA 2023 on NK-cell engager targeting CD123, which is showing very promising data. This was a Phase I study, dose finding study, where several dosages were given. And what was very encouraging about this is, one: it is not toxic, it’s very well tolerated regimen – we always worry about, you know, cell engagers as having significant cytokine release syndrome which has marred the development of some of these agents, but this particular one, we seem to actually not have very significant cytokine release syndrome – so very well tolerated. And the second thing that’s encouraging is in one particular dose level, there was about 35% response rates in terms of complete remissions or incomplete complete remissions – CR/CRi. That’s very encouraging in a Phase I data. So obviously this is going to move forward with the additional enrollment and we’re excited to see what the what the drug does for our relapsed patients.
Read more...
Disclosures
BMS, Servier, Janssen Research
